Abstract
Purpose
Androgen deprivation therapy (ADT) has broad application in the treatment of prostate cancer (PC) and is associated with numerous, debilitating adverse effects. Increasing use of ADT for PC, longer timeframe for treatment (increased uptake of PSA testing and earlier diagnosis), as well as improved survival and an ageing population, means patients can live for a considerable period of time on or after ADT, experiencing these adverse effects. A number of systematic reviews of adverse effects of ADT for PC exist; however, no single systematic review has previously examined the evidence for all adverse effects, including newer forms of ADT.
Methods
A systematic review of existing systematic reviews of ADT for PC was conducted (2010–February 2019), as per Cochrane guidelines, to identify the highest level of risk/incidence evidence available, supplemented by evidence drawn from individual studies where no systematic review existed.
Results
Incidence data was generated for 19 adverse effect subgroups, classified according to the common terminology criteria for adverse events (CTCAE).
Conclusion
Incidence of adverse effects provides valuable information for future burden of disease studies. This information can better guide clinical management to reduce symptoms for patients and assist patients to make more informed decisions about their treatment, potentially improving disease outcomes. It also highlights the importance of supportive care for PC patients receiving ADT and their carers. For analysts conducting economic evaluations, the inclusion of adverse effects in PC decision analytic models can provide more comprehensive and accurate information for decision makers.
Similar content being viewed by others
References
Kumar S, Shelley M, Harrison C, Coles B (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. The Cochrane Collaboration [Internet] (4):1–71
Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD (2009) Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 35(7):540–546
Sharifi N, Gulley JL, Dahut WL (2010) An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 17(4):R305–RR15
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate cancer. https://www.nccn.org/: NCCN; 2018. Accessed 15 April 2019
National Institute of Cancer. NCI Dictionary of Cancer Terms Maryland: National Institutes of Health, US Department of Health and Human Services; 2015 [Available from: http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=444960. Accessed 4 Apr 2019
Australian Institute of Health and Welfare (AIHW). Prostate cancer in Australia. Canberra: AIHW; 2013
Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M (2015) Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 68(3):386–396
Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M (2015) Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One 10(3):e0117344
Fagerlund A, Cormio L, Palangi L, Lewin R, Di Pompeo FS, Elander A et al (2015) Gynecomastia in patients with prostate cancer: A systematic review. PLoS ONE 10(8)
Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, Xiang S, Wang S (2018) Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 21(4):451–460
Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 4(2):128–139
Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, Cui C, Xu T, Yu W, Jin J (2016) A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis 19(4):333–339
Kim D, Lee J, Kim K, H N, Kim J, Hah Y et al (2019) Effect of androgen-deprivation therapy on bone mineral density in patients with prostate cancer: a systematic review and meta-analysis. J Clin Med 8(113)
Kunath F, Grobe HR, Rucker G, Motschall E, Antes G, Dahm P et al (2015) Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review. BJU Int 116(1):30–36
Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E et al (2015) Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncology 1(9):1261–1269
McGinty HL, Phillips KM, Jim HSL, Cessna JM, Asvat Y, Cases MG, Small BJ, Jacobsen PB (2014) Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer 22(8):2271–2280
Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y et al (2016) Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer 16:180
Nead K, Boldbaatar N, Yang D, Sinha S, Nguyen P (2018) Association of androgen deprivation therapy and thromboembolic events: a systematic review and meta-analysis. J Urol 114:155–162
Nead KT, Sinha S, Nguyen PL (2017) Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 20(3):259–264
Nead KT, Sinha S, Yang DD, Nguyen PL (2017) Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urologic Oncology 35(11):664.e1–664.e9
Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 306(21):2359–2366
Roviello G, Sigala S, Danesi R, Re MD, Bonetta A, Cappelletti MR et al (2016) Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials. Crit Rev Oncol Hematol 101:12–20
Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF, STOPCaP Abiraterone Collaborators (2017) Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 84:88–101
Scailteux LM, Naudet F, Alimi Q, Vincendeau S, Oger E (2016) Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: a systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine. 95(24):e3873
Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M et al (2016) A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine. 95(27):e3845
Sun M, Cole A, Hanna N, Mucci L, Berry D, Basaria S, Ahern DK, Kibel AS, Choueiri TK, Trinh QD (2018) Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol 199:1417–1425
Wang H, Sun X, Zhao L, Chen X, Zhao J (2016) Androgen deprivation therapy is associated with diabetes: evidence from meta-analysis. Journal of Diabetes Investigation 7(4):629–636
Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y (2014) Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One 9(9):e107516
Zhu J, Liao R, Su C, Liang D, Wu J, Qiu K, Li J (2018) Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. Expert Rev Anticancer Ther 18(2):193–198
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011. Available from: http://handbook.cochrane.org
Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Bmj. 339:b2700
National Institutes of Health and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In: Services UDoHaH, editor.: US Government; 2017
OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence Oxford: Oxford Centre for Evidence-Based Medicine; 2016 [Available from: http://www.cebm.net/index.aspx?o=5653
Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document) Oxford: Oxford Centre for Evidence-Based Medicine; 2016 [Available from: http://www.cebm.net/index.aspx?o=5653
Shea B, Reeves B, Wells G, Thuku M, Hamel C, Moran J et al (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj. 358
Higgins J, Sterne J, Savović J, Page M, Hróbjartsson A, Boutron I et al (2016) A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 10
Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Ottawa: The Ottawa Hospital Research Institute; 2019
Schunemann H, Cuello C, Akl E, Mustafa R, Meerpohl J, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence 2018
Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS et al (2014) Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis 17(4):338–342
Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104(6):800–805
Greenspan SL, Nelson JB, Trump DL, Resnick NM, Miller M (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146(6):416–424
Ng HS, Koczwara B, Roder D, Vitry A (2018) Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis 21(3):403–410
Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL (2013) Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 111(5):745–752
Wallis C, Mahar A, Satkunasivam R, Hershorn S, Kodama R, Lee Y et al (2016) Cardiovascular and skeletal-related events folowing localised prostate cancer treatment: role of surgery, radiotherapy, and androgen deprivation. J Urol 97:145–152
Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE et al (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–923
Sun M, Choueri T, Hamnvik O-P, Preston M, De Velasco G, Jiang W et al (2016) Comparison of Gonadotrophin-releasing hormone agonists and orchiectomy. JAMA Oncology 2(4):500–507
Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL (2017) Risks of serious toxicities from intermittent versus continuous androgen deprivation therapy for advanced prostate cancer: a population based study. J Urol 197(5):1251–1257
Beebe-Dimmer J, Cetin K, Shahinian V (2012) Timing of androgen deprivation therapy and fracture among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf 21:70–78
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators (2018) Apalutamide treatment and metastasis-free survival in prostate Cancer. N Engl J Med 378(15):1408–1418
Graff J, Baciarello G, Armstrong A, Higano C, Iversen PW, Flaig W et al (2016) Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 27:286–294
Morote J, Gomez-Caamano J, Alvarez-Ossorio J, Pesqueira D, Tabernero A, Veiga F et al (2015) The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol 193(6):1963–1969
Smith M, Lee H, McGovern F, Fallon M, Goode M, Zeitman A (2008) Metabolic changes during gonadotrophin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 112:2188–2194
Keating N, O'Malley J, Smith M (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448–4456
Taylor L, C SE, Du X (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate. Cancer. 115(11):2388–2399
Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, Muraglia A, Porcaro AB, Siracusano S, Brunelli M, Mazzarotto R, Artibani W, Tortora G (2018) The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clinical Genitourinary Cancer 16(3):e645–ee53
Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY (2018) A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer. Eur Urol 73(2):156–165
Gild P, Cole AP, Krasnova A, Dickerman BA, von Landenberg N, Sun M, Mucci LA, Lipsitz SR, Chun FK, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Trinh QD (2018) Liver disease in men undergoing androgen deprivation therapy for prostate cancer. J Urol 200(3):573–581
National Institute for Health and Care Excellence (NICE). Clinical guideline [CG175] Managing adverse effects of hormone therapy UK: NICE; 2014 [updated January 2014
Daly PE, Dunne MT, O'Shea CM, Finn MA, Armstrong JG (2012) The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4-versus 8-month randomised trial (Irish clinical oncology research group 97-01). Radiother Oncol 104(1):96–102
Jones C, Hunt D, McGowan D, Amin M, Chetner M, Bruner D et al (2011) Radiotherapy and short-term androgen deprivation therapy for localized prostate cancer. The New England Journal of Medicine 365(2)
Sharpley C (2007) Actual change in anxiety and depression among Australian men with prostate cancer. Journal of Men's Health and Gender 4(1):32–38
Lee M, Jim HS, Fishman M, Zachariah B, Heysek R, Biagioli M, Jacobsen PB (2015) Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psycho-Oncology. 24(4):472–477
Himelhoch S, Weller W, Wu A, Anderson G, Cooper L (2004) Chronic medical illness, depression, and use of acute medical services among Medicare beneficiaries. Med Care 42:512–521
Roviello G, Generali D (2018) Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. Med Oncol 35(3):29
Alibhai SM, Breunis H, Timilshina N, Naglie G, Tannock I, Krahn M et al (2015) Long-term impact of androgen-deprivation therapy on physical function and quality of life. Cancer. 121(14):2350–2357
Gonzalez B, Jim H, Small B, Sutton S, Fishman M, Zachariah B, Heysek RV, Jacobsen PB (2016) Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer 24:2201–2207
Galvão D, Taaffe D, Spry N, Joseph D, Turner D, Newton R (2009) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12:198–203
Hussain S, Breunis H, Timilshina N, Alibhai SMH (2010) Falls in men on androgen deprivation therapy for prostate cancer. Journal of Geriatric Oncology 1(1):32–39
Graff J, Baciarello G, Armstrong A, Higano C, Iversen P, Flaig T, Forer D, Parli T, Phung D, Tombal B, Beer TM, Sternberg CN (2016) Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrate resistant prostate cancer: results from PREVAIL. Ann Oncol 27:286–294
Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, Bianco BA, Chang P, Pompeo AC, Tobias-Machado M (2015) Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol 33(9):1281–1289
Bourke L, Kirkbride P, Hooper R, Rosario A, Chico T, Rosario D (2013) Endocrine therapy in prostate cancer: time for reapprisal of risks, benefits and cost-effectiveness? Br J Cancer 108:9–13
Pearce A, Haas M, Viney R (2013) Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review. Applied Health Economics and Health Policy 11:619–637
Funding
Kim Edmunds’ PhD was supported by an Australian Post Graduate Awards (APA) Scholarship and an Inspiring Minds Scholarship from Edith Cowan University, WA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 47 kb)
Rights and permissions
About this article
Cite this article
Edmunds, K., Tuffaha, H., Galvão, D.A. et al. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Support Care Cancer 28, 2079–2093 (2020). https://doi.org/10.1007/s00520-019-05255-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-019-05255-5